Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

LSTA

Lisata Therapeutics Inc

Dec 13 • 04:00PM ET

2.58

Dollar change -0.15
Percentage change -5.49	%

Healthcare • Biotechnology • USA • NASD

Peers: GERN BCLI ALLO BEAM CRSP EDIT FATE NTLA RGNX SRPT

| Held by: VTI VXF DFUS DFAS DFAC DFAT DFSU DCOR DXUV

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-2.51	Insider Own	17.54%	Shs Outstand	8.32M	Perf Week	-4.83%
Market Cap	20.47M	Forward P/E	-	EPS next Y	-2.35	Insider Trans	0.00%	Shs Float	6.92M	Perf Month	-7.53%
Income	-20.74M	PEG	-	EPS next Q	-0.76	Inst Own	9.13%	Short Float	0.22%	Perf Quarter	-11.34%
Sales	0.00M	P/S	-	EPS this Y	-3.10%	Inst Trans	1.83%	Short Ratio	0.95	Perf Half Y	-28.33%
Book/sh	4.05	P/B	0.64	EPS next Y	11.47%	ROA	-43.08%	Short Interest	0.02M	Perf Year	-12.54%
Cash/sh	4.52	P/C	0.57	EPS next 5Y	-	ROE	-47.87%	52W Range	2.19 - 3.83	Perf YTD	-5.49%
Dividend Est.	-	P/FCF	-	EPS past 5Y	36.51%	ROI	-61.56%	52W High	-32.64%	Beta	1.18
Dividend TTM	-	Quick Ratio	8.03	Sales past 5Y	0.00%	Gross Margin	-	52W Low	17.81%	ATR (14)	0.20
Dividend Ex-Date	-	Current Ratio	8.03	EPS Y/Y TTM	6.52%	Oper. Margin	-	RSI (14)	40.08	Volatility	13.21% 7.04%
Employees	25	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	14.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	8.31%	Payout	-	Rel Volume	0.54	Prev Close	2.73
Sales Surprise	-	EPS Surprise	21.33%	Sales Q/Q	-	Earnings	Nov 12 AMC	Avg Volume	15.86K	Price	2.58
SMA20	-6.69%	SMA50	-9.82%	SMA200	-15.13%	Trades		Volume	8,560	Change	-5.49%

Dec-11-24 10:52AM	Lisata completes subject enrolment in multi-cancer trial of certepetide (Clinical Trials Arena) -6.93%
10:28AM	Lisata Therapeutics Completes Enrollment for Cancer Therapy Trial (Exec Edge)
Dec-10-24 08:30AM	Lisata Therapeutics Announces Completion of Enrollment in the CENDIFOX Trial (GlobeNewswire) +6.63%
Dec-04-24 06:28AM	Lisata and Kuva Labs partner for MR imaging agents to detect cancer (Medical Device Network)
Dec-03-24 08:30AM	Lisata Therapeutics and Kuva Labs Announce Global License Agreement for Solid Tumor Imaging (GlobeNewswire)
08:30AM	Loading…
Nov-19-24 08:30AM	Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for 'Specialized BioTherapeutics Company of the Year' (GlobeNewswire)
Nov-13-24 08:44AM	Q3 2024 Lisata Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
02:16AM	Lisata Therapeutics Inc (LSTA) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Cost ... (GuruFocus.com)
Nov-12-24 04:05PM	Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Nov-06-24 09:23AM	Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration (GlobeNewswire)
08:30AM	Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024 (GlobeNewswire)
Nov-01-24 12:00PM	Lisata Therapeutics, Inc. (LSTA) Upgraded to Buy: Here's What You Should Know (Zacks) +11.66%
Oct-31-24 08:30AM	Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events (GlobeNewswire)
Oct-28-24 08:30AM	Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis (GlobeNewswire)
Oct-03-24 08:00AM	Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events (GlobeNewswire)
08:00AM	Loading…
Sep-17-24 08:00AM	Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial (GlobeNewswire) +6.53%
Sep-09-24 08:00AM	Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events (GlobeNewswire)
Sep-05-24 08:00AM	Lisata Therapeutics' Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma (GlobeNewswire) +9.00%
Aug-12-24 04:05PM	Lisata Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-05-24 08:00AM	Lisata Therapeutics to Report Second Quarter 2024 Financial Results and Provide a Business Update on Monday, August 12, 2024 (GlobeNewswire) -8.72%
Jul-19-24 06:32AM	Lisata to use Haystacks MRD tests for pancreatic cancer therapy trial (Medical Device Network)
Jul-18-24 11:13AM	Haystack Oncology, Lisata Therapeutics Collaborate on Pancreatic Cancer Therapy (Exec Edge)
08:00AM	Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD Technology to Evaluate Efficacy of Pancreatic Cancer Therapy (GlobeNewswire)
07:30AM	EXCLUSIVE: Haystack Oncology Inks Research Collaboration With Lisata Therapeutics To Use Haystack MRD Technology To Evaluate Pancreatic Cancer Therapy Efficacy (Benzinga)
Jul-16-24 10:22AM	Lisata (LSTA) Stock Rallies More Than 30% YTD: Here's Why (Zacks)
08:00AM	Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma (GlobeNewswire)
Jul-10-24 08:00AM	Lisata Therapeutics' Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model (GlobeNewswire)
Jun-14-24 09:20AM	Lisata Therapeutics Hits Enrollment Milestone for Pancreatic Cancer Trial (Exec Edge)
09:19AM	Lisata Therapeutics CEO encouraged by progress on pancreatic cancer trial (News Direct)
Jun-13-24 08:30AM	Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial (GlobeNewswire)
08:30AM	Loading…
May-28-24 08:30AM	Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events (GlobeNewswire)
May-20-24 03:58PM	Sector Update: Health Care Stocks Softer Late Afternoon (MT Newswires)
11:14AM	Lisata Therapeutics Receives European Medicines Agency Pediatric Waiver for Pancreatic Cancer Treatment (MT Newswires)
08:30AM	Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer (GlobeNewswire)
May-13-24 10:45AM	Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results (News Direct) -5.93%
May-10-24 12:39PM	Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q1 2024 Earnings Call Transcript (Insider Monkey)
12:10PM	Q1 2024 Lisata Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
May-09-24 05:47PM	Lisata Therapeutics Net Loss Declines From a Year Earlier (Exec Edge) +5.93%
04:05PM	Lisata Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-08-24 08:00AM	Lisata Therapeutics to Participate in Upcoming May 2024 Industry and Investor Events (GlobeNewswire)
May-02-24 08:00AM	Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024 (GlobeNewswire)
Apr-23-24 10:48AM	Lisata Therapeutics advances lead asset LSTA1 for treatment of advanced solid tumors (News Direct)
09:48AM	Lisata Therapeutics, Qilu Pharmaceutical Dose First Patient in China Trial of LSTA1 Plus Chemo for Pancreatic Cancer (MT Newswires)
07:30AM	Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (GlobeNewswire)
Apr-10-24 09:53AM	Lisata's (LSTA) LSTA1 Gets FDA Orphan Drug Tag for Osteosarcoma (Zacks)
Apr-09-24 08:30AM	Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma (GlobeNewswire)
Apr-03-24 08:30AM	Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events (GlobeNewswire)
Mar-22-24 12:25PM	Lisata's (LSTA) LSTA1 Gets FDA's RPDD Tag for Osteosarcoma (Zacks)
Mar-21-24 08:00AM	Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma (GlobeNewswire) +8.41%
Mar-08-24 08:35AM	Life Science Virtual Investor Forum Presentations Now Available for Online Viewing (GlobeNewswire)
Mar-05-24 08:35AM	Life Science Virtual Investor Forum Agenda Announced for March 7th, 2024 (GlobeNewswire)
Mar-04-24 08:00AM	Lisata Therapeutics to Present at the Life Science Investor Forum on March 7 (GlobeNewswire)
Mar-02-24 08:29AM	Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-01-24 08:29AM	Q4 2023 Lisata Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +5.80%
Feb-29-24 04:05PM	Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire) -7.26%
Feb-22-24 08:00AM	Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time (GlobeNewswire)
Feb-20-24 08:00AM	Lisata Therapeutics to Present at BIO CEO & Investor Conference (GlobeNewswire)
Jan-23-24 12:12PM	Lisata (LSTA) Stock Up More Than 35% in 3 Months: Here's Why (Zacks)
Jan-18-24 08:30AM	Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico (GlobeNewswire)
Jan-17-24 08:00AM	Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme (GlobeNewswire)
Jan-04-24 08:00AM	Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy (GlobeNewswire) +7.86%
Dec-12-23 08:00AM	Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma (GlobeNewswire) +12.60%
Nov-28-23 04:05PM	Lisata Therapeutics to Present at NobleCon19 Investor Conference (GlobeNewswire)
Nov-09-23 04:05PM	Lisata Therapeutics Announces Participation in Upcoming Conferences in November (GlobeNewswire) -5.80%
Nov-07-23 12:00PM	All You Need to Know About Lisata Therapeutics, Inc. (LSTA) Rating Upgrade to Buy (Zacks)
Nov-05-23 12:18PM	Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-03-23 07:50AM	Q3 2023 Lisata Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +8.26%
Nov-02-23 04:05PM	Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-26-23 08:00AM	Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 2nd at 4:30 p.m. Eastern Time (GlobeNewswire)
Oct-24-23 08:00AM	Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide (GlobeNewswire)
Oct-18-23 11:13AM	Lisata's (LSTA) Lead Cancer Drug Gets EC's Orphan Tag, Stock Up (Zacks)
Oct-17-23 08:00AM	Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer (GlobeNewswire) +6.60%
Sep-28-23 08:00AM	Lisata Therapeutics Announces Participation in Upcoming Conferences in October (GlobeNewswire)
Sep-20-23 08:00AM	Lisata Therapeutics Announces Participation in InfoSec World 2023 (GlobeNewswire) -7.98%
Sep-12-23 08:00AM	Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid Tumors (GlobeNewswire)
Sep-07-23 12:58PM	Lisata (LSTA) Up on Positive Updates for Pancreatic Cancer Study (Zacks) -13.51%
Sep-06-23 08:00AM	Lisata Therapeutics Announces Outcome of Interim Futility Analysis for its Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma (GlobeNewswire) +10.89%
Sep-05-23 08:00AM	Lisata Therapeutics Announces Participation in Upcoming Conferences in September (GlobeNewswire)
Aug-19-23 07:52AM	Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-15-23 11:58PM	Q2 2023 Lisata Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
08:30AM	Impilo Therapeutics Launches to Enable Nucleic Acid-Based Medicines to Effectively Treat Solid Tumor Cancers (PR Newswire)
Aug-14-23 04:05PM	Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Aug-08-23 08:00AM	Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Malignant Glioma (GlobeNewswire)
Aug-07-23 08:30AM	Lisata Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14 After Market Trading and to Host Conference Call on Tuesday, August 15 at 8:30 a.m. Eastern Time (GlobeNewswire)
Jul-11-23 08:30AM	Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors (GlobeNewswire)
Jun-12-23 08:30AM	Lisata Therapeutics to Present at the GCFF Innovation and Healthcare Virtual Conference (GlobeNewswire)
May-24-23 08:00AM	Lisata Therapeutics Announces Enhancements to Ongoing Phase 2b ASCEND Trial of LSTA1 (GlobeNewswire)
May-09-23 04:05PM	Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
May-02-23 09:07AM	Lisata Therapeutics to Host First Quarter 2023 Financial Results Conference Call on Tuesday, May 9th, at 4:30 p.m. Eastern Time (GlobeNewswire)
Apr-27-23 09:00AM	Lisata Therapeutics Announces Participation in Upcoming Conferences in May (GlobeNewswire)
Apr-20-23 08:30AM	Lisata Therapeutics Receives $2.2 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program (GlobeNewswire)
08:13AM	Amgen (AMGN) Wins Patent Appeal for Blockbuster Psoriasis Drug (Zacks)
Apr-19-23 08:30AM	Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico (GlobeNewswire)
Apr-18-23 08:30AM	Lisata Therapeutics and WARPNINE Announce First Patient Treated in the iLSTA Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma (GlobeNewswire)
Apr-05-23 09:34AM	4 Medical Stocks to Buy as Rate Hike Cycle Nears End (Zacks)
Mar-30-23 04:05PM	Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Mar-23-23 08:30AM	Lisata Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call on Thursday, March 30, 2023, at 4:30 p.m. Eastern Time (GlobeNewswire)
Mar-10-23 08:35AM	Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire) -8.88%
Mar-07-23 08:35AM	Life Sciences Virtual Investor Forum Agenda Announced for March 9th (GlobeNewswire)

Lisata Therapeutics, Inc. is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Its product, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to target and penetrate tumors. It also actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs more efficiently penetrating and accumulating in the tumor, while normal tissues are unlikely to be affected. The company was founded in 1980 and is headquartered in Basking Ridge, NJ.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LSTA

Lisata Therapeutics Inc

Upgrade your FINVIZ experience